Diligence memo · auto-generated · as of July 2, 2026
Pheast Therapeutics, Inc.
Pheast Therapeutics, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Pheast Therapeutics, Inc. operates in Pharma, based in REDWOOD CITY.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pheast Therapeutics, Inc. has raised $100M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $75M on 2022-01-31.
Most recent recorded round closed around 2025-10-07.
Valuation (modeled)modeled
Provath models Pheast Therapeutics, Inc. at approximately $139M (range $80M–$177M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.46× the median modeled value of Series C Pharma companies in 2025–2027 (6 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 22 months.
Last raise 9 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 3.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 91% of Pharma peers (310 compared).
Modeled value ranks above 72% of those peers.
Closest niche peers: Click Therapeutics, Inc., Allay Therapeutics, Inc., Somite Therapeutics, Inc., Indapta Therapeutics Inc., Bryn Pharma, LLC.
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.